Home
    • Plans Blog Contact
    Edwards Lifesciences Corp logo

    Edwards Lifesciences Corp

    EW
    Last price US$83.25
    Market cap US$53.2b
    12M price change 9.62%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Abbott LaboratoriesABT Industry peer DexCom IncDXCM Industry peer Iradimed CoIRMD Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Edwards Lifesciences Corp Overview

    Industry: Medical Devices

    Sector: Healthcare

    Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of hea Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Edwards Lifesciences Corp into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Jul 23, 2026

    Quarterly result summary

    Net sales was $1.7B (+14% YoY); EPS was $2.95 (reported).

    Net sales $1.7B +14% YoY
    EPS $2.95 reported
    Operating income -$21.3M -15% YoY
    Net income $241.4M -27% YoY

    What changed

    • Net sales +14% YoY to $1.7B; EPS reported to $2.95.
    • Operating income -15% YoY to -$21.3M.
    • Net income -27% YoY to $241.4M.

    Guidance / outlook

    The company expects the value of its growing body of clinical evidence will further increase with time, as demonstrated by recent reductions in all-cause mortality and heart failure hospitalizations, and will support continued physician adoption and expansion of access for patients with tricuspid regurgitation.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K Jul 23, 2026 SEC filing 10-Q May 06, 2026 SEC filing 8-K Apr 23, 2026 Earnings release Earnings release Apr 23, 2026 SEC filing 10-K Feb 25, 2026 Earnings release Earnings release Feb 10, 2026 SEC filing 8-K Feb 10, 2026 SEC filing 10-Q Nov 05, 2025 SEC filing 8-K Oct 30, 2025 Earnings release Earnings release Oct 30, 2025 SEC filing 10-Q Aug 06, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Edwards Lifesciences Corp boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Iradimed Co are companies with high ratings.

    Return on Equity

    Score 2.61/5
    Edwards Lifesciences Corp stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Edwards Life... EW US$53.2b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 3.94/5
    Edwards Lifesciences Corp commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Edwards Life... EW US$53.2b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Iradimed Co are companies with high ratings.

    Leverage

    Score 2.80/5
    Edwards Lifesciences Corp attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Edwards Life... EW US$53.2b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Edwards Lifesciences Corp logo

    Edwards Lifesciences Corp

    US$83.25

    US$45.41

    -45.5% vs price

    US$53.2b

    -3.55%

    9.62%